Strategic partnerships Celonic is actively forming strategic collaborations with Leukocare, Carbogen Amcis, Merck, and Lindis Biotech to expand capabilities in perfusion-based bioprocessing, ADC development, and commercial supply. This indicates a readiness to partner for integrated solutions across development and manufacturing stages, presenting opportunities for joint selling of end-to-end CDMO services.

Commercial-scale potential Recent multi-year commercial manufacturing agreements for catumaxomab and ADC development indicate Celonic’s trajectory toward long-term supply partnerships with biotech companies. This creates upsell opportunities around expanded cell culture capacity, scale-up services, and late-stage manufacturing for existing clients.

Perfusion capability Integration of Merck’s Breez micro-bioreactor platform and emphasis on perfusion-based bioprocessing position Celonic as a go-to provider for high-efficiency, scalable biologics manufacturing. This appeals to biotech firms seeking robust early-to-late-stage perfusion solutions and high productivities.

Geographic strengths With a Basel headquarters and Heidelberg facilities, Celonic combines Swiss innovation with German manufacturing capability. This cross-border footprint can be leveraged to win customers in EU markets seeking nearby, quality-focused CDMO partners with a proven track record.

Leadership and growth Leadership continuity with CEO Samanta Cimitan and a growing workforce signals stability and capacity expansion, presenting a narrative for potential customers about reliable project execution, additional recruitment capacity for increasing demand, and continued investment in next-generation bioprocessing technologies.